clinical trial · NCT04755283
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Anthos Therapeutics, Inc.·phase2·active not recruiting·n = 1,287
Atrial Fibrillation (AF)StrokeAbelacimabRivaroxaban
brief summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
started
Feb 2, 2021
primary completion
Feb 15, 2024
completion
Dec 29, 2028
last updated
Nov 6, 2025
official title
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol